Novartis rethinks CML strategy for next-gen allosteric drug due for a pivotal readout later this year
In the leadup to a “major expected” Phase III trial readout for asciminib in third-line chronic myelogenous leukemia, Novartis has unceremoniously removed a planned filing for the same drug as an earlier line of therapy — which is still being tested in Phase II.
The Swiss pharma giant gave the update on asciminib, also dubbed ABL001, exactly one line in its 160-page presentation on Q4 and FY 2019 results, alongside a disclosure that it’s dropped a Phase III for Ilaris (canakinumab) in hereditary periodic fevers.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters
